Ectopic ACTH secretion syndrome
MONDO:0043472A syndrome characterized by abnormal secretion of adrenocorticotrophic hormone in conjunction with neoplastic growth occurring anywhere in the body. The most common associations are tumors of the bronchus (oat cell or carcinoid), thymic tumors (epithelial or carcinoid), and pancreatic endocrine tumor. (DeVita et al. Cancer, p 1364. 4th edition. Lippincott)
Also known as: ectopic ACTH secretion, ectopic ACTH secretion syndrome, ectopic ACTH syndrome, hypercortisolism due to nonpituitary tumor, hypercortisolism due to nonpituitary tumour, ACTH syndromes, ectopic, ectopic ACTH secretion causing Cushing's syndrome, ectopic ACTH syndromes
20 clinical trials for this condition and its sub-types, 15 tagged with Ectopic ACTH secretion syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug shows promise for Long-Term control of cushing syndrome
Disease control OngoingThis study looks at the long-term safety of relacorilant, a drug for people with Cushing syndrome. It includes 125 adults who previously completed a relacorilant study and may benefit from continued treatment. Researchers will track side effects over time to see if the drug is sa…
Phase 2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New pill could tame hormone disorder Cushing's syndrome
Disease control OngoingThis early-stage study tests an experimental pill called CRN04894 in 18 adults with Cushing's syndrome caused by too much ACTH hormone. The drug works by blocking the receptor that ACTH acts on, aiming to lower cortisol levels and control the disease. The main goals are to check …
Phase 1/2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a drug tame excess cortisol? new trial tests metyrapone
Disease control OngoingThis phase 2 trial tests whether metyrapone, a drug that lowers cortisol production, is safe and effective for people with mild autonomous cortisol secretion (MACS). About 30 participants will take the drug for a period, and researchers will track side effects and cortisol levels…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Wearable tech puts hormone health to the test
Knowledge-focused OngoingThis trial tests whether wearable devices can measure how the body responds to everyday challenges like changes in salt intake, meals, fasting, and exercise in adults with endocrine or metabolic disorders. Participants wear home monitoring devices and follow different diet and ac…
Sponsor: Felix Beuschlein • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC